文献速递淋巴瘤

鸡源CD20抗体具有强效B细胞清除活性

Chicken-derived CD20 antibodies with potent B-cell depletion activity.
PubMed 文献 · Br J Haematol · 2022-08-30

研究报道了从鸡中发现的四种新型抗人CD20单克隆抗体,其鸡-人嵌合抗体在抗体依赖性细胞毒作用和补体依赖性细胞毒作用上均优于利妥昔单抗,在全血中清除B细胞的能力较利妥昔单抗强20-100倍,并在体内保持疗效。其中AC1可结合小鼠CD20,人源化版本hAC11-10保留了亲本抗体的活性。

要点

  • 鸡-人嵌合抗CD20抗体ADCC较利妥昔单抗增强至少10倍,CDC增强4-8倍。
  • 在全血中清除B细胞的能力较利妥昔单抗强20-100倍,并在体内保持疗效。
  • AC1可结合小鼠CD20,提示针对现有人源CD20抗体无法触及的新表位。

核心结论

  • 这些鸡源抗人CD20单克隆抗体是有望改善淋巴细胞恶性肿瘤当前不理想临床结局的候选单药,并为下一代CD20介导的免疫治疗提供分子库。

研究设计与样本

  • 从鸡中发现的四种新型抗人CD20单克隆抗体的临床前研究。

主要发现

  • 鸡-人嵌合抗体的ADCC较利妥昔单抗增强至少10倍,CDC增强4-8倍。
  • 在全血中清除B细胞的能力较利妥昔单抗强20-100倍,并在体内保持疗效。
  • AC1可结合小鼠CD20,提示针对现有人源CD20抗体无法触及的新表位。
  • 人源化抗体hAC11-10保留了亲本抗体的ADCC、体外全血B细胞清除和体内淋巴瘤细胞清除活性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report four novel anti-human CD20 (hCD20) monoclonal antibodies (mAbs) discovered from a phylogenetically distant species-chickens. The chicken-human chimaeric antibodies exhibit at least 10-fold enhanced antibody-dependent cellular cytotoxicity (ADCC) and 4-8-fold stronger complement-dependent cytotoxicity (CDC) relative to the clinically used mouse-human chimaeric anti-hCD20 antibody rituximab (RTX). Thus, to our knowledge these mAbs are the first to significantly outperform RTX in both Fc-mediated mechanisms of action. The antibodies show 20-100-fold superior depletion of B cells in whole blood from healthy humans relative to RTX and retain efficacy in vivo. One of the mAbs, AC1, can bind mouse CD20, indicating specificity for a novel hCD20 epitope inaccessible to current (mouse-derived) anti-hCD20 mAbs. A humanized version of one antibody, hAC11-10, was created by complementarity-determining region (CDR) grafting into a human variable region framework and this molecule retained the ADCC, in vitro human whole-blood B-cell depletion, and in vivo lymphoma cell depletion activities of the parent. These mAbs represent promising monotherapy candidates for improving upon current less-than-ideal clinical outcomes in lymphoid malignancies and provide an arsenal of biologically relevant molecules for the development of next-generation CD20-mediated immunotherapies including bispecific T-cell engagers (BiTE), antibody-drug conjugates (ADC) and chimaeric antigen receptor-engineered T (CAR-T) cells.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chockalingam K, Kumar A, Song J, et al. Chicken-derived CD20 antibodies with potent B-cell depletion activity. Br J Haematol. 2022. PMID: 36039695. doi:10.1111/bjh.18438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。